Hualan Biological Engineering Inc.
002007
Clasificación en acciones
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Precio por acción
$1.92
Capitalización bursátil
$3.50B
Cambio (1 día)
-1.39%
Cambio (1 año)
-19.45%
País
CN
Comercio Hualan Biological Engineering Inc. (002007)
Categoría
Healthcare
Ratio P/E de Hualan Biological Engineering Inc. (002007)
Ratio P/E al October 2026 TTM: 28.52
Según los últimos informes financieros y el precio de las acciones de Hualan Biological Engineering Inc., el P/E actual (TTM) de la empresa es 28.52. Al final de 2024, la empresa tenía un P/E de 28.28.
Historial del ratio P/E de Hualan Biological Engineering Inc. desde 2001 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 28.52 | -2.00% |
| 2025 | 29.10 | 2.89% |
| 2024 | 28.28 | 3.77% |
| 2023 | 27.25 | -28.96% |
| 2022 | 38.36 | -6.10% |
| 2021 | 40.85 | -14.18% |
| 2020 | 47.61 | 24.38% |
| 2019 | 38.27 | 56.86% |
| 2018 | 24.40 | -23.37% |
| 2017 | 31.84 | -25.26% |
| 2016 | 42.60 | -1.87% |
| 2015 | 43.41 | 20.83% |
| 2014 | 35.93 | 3.05% |
| 2013 | 34.86 | -13.74% |
| 2012 | 40.42 | 3.92% |
| 2011 | 38.89 | -14.59% |
| 2010 | 45.54 | 38.85% |
| 2009 | 32.80 | -27.63% |
| 2008 | 45.31 | -53.01% |
| 2007 | 96.43 | 116.95% |
| 2006 | 44.45 | 196.71% |
| 2005 | 14.98 | 1.61% |
| 2004 | 14.74 | -17.77% |
| 2003 | 17.93 | -18.71% |
| 2002 | 22.05 | -46.45% |
| 2001 | 41.19 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | 0.93% |
US
|
|
| -28.36 | -199.44% |
US
|
|
| -25.99 | -191.14% |
AU
|
|
| 31.22 | 9.47% |
NL
|
|
| 17.49 | -38.67% |
BE
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.